Filing identity and reporting period
Important identity mismatch: The supplied filing is First Light Acquisition Group, Inc.’s Form 10-Q, not a filing by Calidi Biotherapeutics, Inc. It covers the quarter ended September 30, 2021 and, for certain statements, the period from incorporation on March 24, 2021 through September 30, 2021. First Light was a newly formed SPAC and reported no operating business or identified business-combination partner.
Financial results and position
- Revenue: None; the company said it would not generate operating revenue before completing a business combination.
- Net loss: $823,289 for the three months ended September 30, 2021 and $906,592 from inception through September 30, 2021. Quarterly operating costs were $1,094,880; inception-to-date costs were $1,178,183. Other income, principally a $283,000 gain from the change in warrant fair value, partially offset costs.
- Cash flow: $1,197,342 cash at period-end. Net cash used in operating activities was $1,588,333; $230 million was placed in the Trust Account. Financing activities provided $232,785,675.
- Assets and liquidity: Total assets were $232,005,361, including $230,000,423 in Trust Account investments and $2,004,938 in current assets. Current liabilities were $47,901; reported working capital was $1,957,037. Trust funds were generally restricted pending a business combination, redemptions, or liquidation.
- Debt and other liabilities: No long-term debt was reported. Total liabilities were $20,980,733, including $12,840,000 of warrant liabilities and $8,050,000 of deferred underwriting fees payable upon a completed business combination. The prior related-party promissory note had been repaid.
- Margins: Not meaningful because the company had no operating revenue.
Material changes and unusual items
The company completed its IPO on September 14, 2021, issuing 23 million units at $10 each for $230 million gross proceeds, and sold private-placement warrants for approximately $5.1 million. It placed $230 million in trust. Since this was its first reporting period after formation and IPO, the filing provides no directly comparable prior-year operating period.
Redeemable Class A shares, totaling $230 million at redemption value, were presented outside permanent stockholders’ equity as temporary equity. The company recorded $20,144,513 of accretion to redemption value. Warrants were classified as liabilities and remeasured at fair value, creating non-operating income or expense. These accounting items affect reported results and are not evidence of operating performance.
Outlook, risks, and contingencies
- Management had not identified a target or begun substantive discussions on a potential business combination. The company had until September 14, 2022 to complete one, with two possible three-month extensions described; absent completion, public shares would generally be redeemed and warrants could expire worthless.
- Management stated that available resources were insufficient to sustain operations for one year from issuance and disclosed substantial doubt about the company’s ability to continue as a going concern. Sponsor working-capital loans were described as a possible source of support, but no formal agreement existed and no such loans were outstanding at quarter-end.
- A forward purchase agreement contemplated a conditional $50 million investment at a business-combination closing. The filing also describes a $10,000 monthly administrative-services fee and $8.05 million in deferred underwriting fees payable only if a business combination is completed.
- Management was evaluating possible COVID-19 effects. No legal proceedings or material changes to previously disclosed risk factors were reported. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Investor verification points
- Confirm the intended issuer: the provided filing is for First Light Acquisition Group, not Calidi Biotherapeutics.
- Verify the business-combination deadline and extension terms: the filing contains inconsistent dates in different sections, including January 28, 2023 in one passage and September 14, 2022 with possible extensions elsewhere.
- Review the going-concern disclosure and the availability and terms of any sponsor funding, which was not contractually assured.
- Assess trust restrictions, redemption exposure, warrant-liability valuation, and potential dilution from public, private-placement, and forward-purchase warrants and securities.
- Distinguish the $823,289 quarterly net loss in the financial statements from the filing’s inconsistent MD&A loss figures; the financial-statement period values are used above.